Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Men with Prostate Cancer Worse off than Women with Breast Cancer

29.07.2005


Maintaining lifestyle top of men’s list when choosing a prostate cancer therapy

Despite wanting to avoid undesirable side effects, nearly half of men with prostate cancer do not have enough information on the lifestyle impact of treatments

Nearly nine out of 10 healthy men say maintaining their lifestyle is the main priority if they had to receive a hormonal treatment for locally advanced prostate cancer, according to a new study.1 In reality, nearly half of men feel that they are not asked about their lifestyle preferences when discussing treatment options and their effect on quality of life, as results from a new patient survey show.2 In contrast, more than three quarters of women with breast cancer are likely to be asked about their lifestyle preferences when discussing treatment options.2



The study involved 180 healthy men, aged 50 years and over, who were given scenarios describing the details of the two types of hormonal therapies used in locally advanced prostate cancer - either a luteinising hormone releasing analogue (LHRHa), or a non-steroidal anti-androgen (NSAA), such as bicalutamide 150mg – together with a discussion on their side effects. They were then interviewed and asked which type of therapy they would prefer if they were diagnosed with locally advanced prostate cancer.

Professor Lesley Fallowfield, one of the study researchers and Director of Cancer Research UK’s Psychosocial Oncology Group, Brighton and Sussex Medical School, says: “These results suggest that men with locally advanced prostate cancer should be offered not just a choice of treatment but an explanation of how the treatments are given and the impact that their side effects may have on men’s lifestyles.”

Most men would prefer a hormonal therapy that allows them to maintain their lifestyle by avoiding undesirable side effects, such as reduced physical strength and increased risk of bone fractures. Nearly nine out of 10 men say they would prefer NSAA therapy (compared with less than one in 10 choosing an LHRHa), because of a better side effect profile (three quarters of respondents).

Patients with locally advanced prostate cancer have a significant risk of their disease progressing, seriously impacting quality of life. Therefore therapies that improve progression-free survival whilst allowing patients to maintain a normal lifestyle are vital in managing the disease. It has been shown that when patients’ are given the advantages and disadvantages of alternative treatments, they are willing to contemplate trading life expectancy to be relieved of the burden of side effects, such as limitations in physical energy.3

In addition, results from the patient survey show the need for physicians to involve men more when deciding on the choice of treatment. The comparative survey of prostate (n=87) and breast (n=104) cancer patients currently receiving hormonal therapy aimed to look at the differences in behavioural and attitudinal approaches that men and women have towards their disease and its treatment. Findings show that just over half of men with prostate cancer are likely to be asked about their lifestyle preferences by their physician in stark contrast to four out of five women with breast cancer when treatment options are being discussed.2

“Although men are traditionally less likely to talk about illness, especially their own,” says Professor John Masters, Executive Director, the Prostate Cancer Research Centre, University College, London. “These findings show us that not enough is being done to address men’s concerns over side effects of prostate cancer therapies and their impact on lifestyle. Patients need to be involved in the treatment decision process to ensure that they receive the best treatment choice in terms of lifestyle and quality of life.”

Even though nearly two thirds of men with prostate cancer experience side effects with hormonal therapies, less than one in five is willing to discuss the possibility of changing treatment to reduce side effects, compared with more than a third of women with breast cancer.2

Mr Geoffrey Mitchell, a 59-year-old grandfather of three, says that men need to be bolder when it comes to challenging their physicians about treatments and actively seeking more information about their illness. "When I was first diagnosed with prostate cancer, I felt it was very much a case of ’doctor knows best’. Also, the worry of first being told you have cancer meant I couldn’t really think straight at the time. Fortunately, my doctor discussed all the options in detail and we both agreed the most suitable drug for me. The last thing I wanted was to have to give up my active lifestyle and work. We both agreed that I needed a treatment which would mean I could still carry on at work and be there for my children and grandchildren."

The findings from both the preference study and patient survey reinforce the need to offer patients with locally advanced prostate cancer a choice of treatment options, and for physicians to discuss these not only in terms of achieving an effective outcome but also how their side effects will impact on men’s lifestyles and physical activities.

Each year around 30,000 men in the UK alone are diagnosed with prostate cancer, which has overtaken lung cancer to become the most common cancer for men in the UK. Prostate cancer is the second biggest cause of death from cancer in men in the UK with around 10,000 deaths each year and more than 80 per cent of cases are diagnosed in men over 60.4.

Rosie Allan | alfa
Further information:
http://www.hillandknowlton.com

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>